Lilly Launches Phase III Trial of Retatrutide (GLP-1/GIP/GCG Triagonist) for Chronic Lower Back Pain in Obese Patients

▎Armstrong

On June 24, 2025, Eli Lilly and Company registered a Phase III clinical trial on Clinicaltrials.gov for Retatrutide in the treatment of obesity with lower back pain.

This Phase III clinical trial plans to enroll 586 patients with obesity and lower back pain, with a follow-up period of 80 weeks, and is expected to be completed in September 2027.

Low back pain may be triggered by various factors, among which obesity is closely related to low back pain in terms of lifestyle factors.

Summary

Retatrutide is the world's first GLP-1/GIP/GCG triple agonist, with multiple Phase III clinical trials currently underway for weight loss, while also exploring diabetes, chronic kidney disease, and additional new indications.